DNA methylation signature predicts cancer response to demethylation agents from profiling diverse cancer cell lines
Authors:
Open Access
- 18 June 2022
- journal article
- letter
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 42 (8) , 789-792
Abstract
No abstract availableFunding Information
- the Mayo Clinic Center for Individualized Medicine
This publication has 7 references indexed in Scilit:
- Defining Driver DNA Methylation Changes in Human CancerInternational Journal of Molecular Sciences, 2018
- Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromesLeukemia, 2018
- Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancerCell Death & Disease, 2017
- Immunological effects of hypomethylating agentsExpert Review of Hematology, 2017
- The cancer epigenome: Concepts, challenges, and therapeutic opportunitiesScience, 2017
- Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in CancerCancer Research, 2016
- Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen‐specific cellular immunityBritish Journal of Haematology, 2012